Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: when less ESA is more

This article was originally published in Scrip

Executive Summary

The FDA's recommendation on lower doses of erythropoiesis-stimulating agents (ESAs) to treat anaemia, announced on the afternoon of 24 June 2011, had investors scurrying for the exits wiping about $830m from Amgen's market capitalisation. In retrospect, this looks like a knee-jerk reaction to the latest in a long line of safety and commercial concerns for the ESA drug class. What may be lost in the admittedly short-term perspective that investors have taken is that regulatory actions and their reinforcement by the medical profession and reimbursement norms also serve to tighten Amgen's grip on the ESA franchise.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC013464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel